Navigation Links
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
Date:4/6/2011

llion ($15 million per year) over the two years beginning with the first commercial sale of DIFICID. Cubist is also eligible to receive an additional $5 million in the first year after first commercial sale and $12.5 million in the second year of the agreement if mutually agreed upon annual sales targets are achieved, as well as a portion of Optimer's gross profits from any sales above the specified annual sales target levels.

Scheduled Conference Call

Optimer will host a conference call today at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the outcome of the Anti-Infective Drugs Advisory Committee as well as the Cubist collaboration. To participate in the conference call, please dial (877) 280-7280 from the U.S., or (678) 825-8232 for international callers. Please specify to the operator that you would like to join "Optimer's Conference Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call. Please connect to Optimer's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. 

About DIFICID™ (Fidaxomicin)

DIFICID™ (fidaxomicin) is an investigational antibiotic with a novel mechanism of action, which inhibits the bacterial enzyme RNA polymerase, resulting in the rapid killing of C. difficile. The narrow-spectrum profile of DIFICID eradicates C. difficile selectively with minimal disruption to the normal intestinal flora, while the alternative antibiotics used to treat CDI, metronidazole and vancomycin, have been shown to disrupt the gut flora. DIFICID facilitates the return of normal physiological conditions in the colon which may be responsible for reducing CDI recurrence rates. In two Phase 3 trials for the treatment of CD
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
2. Trading Halted Today in Optimer Pharmaceuticals Stock
3. Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
4. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
5. Optimer Pharmaceuticals Announces Issuance of Key Patent Covering Fidaxomicin Methods of Use as a Treatment of Clostridium difficile infection
6. Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
7. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results
8. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
9. Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock
10. Optimer Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Northstar Global Business ... Trust Company (DTC) has made their final decision ... on the Company,s stock effective December 15, 2014, ... stock for depository and book entry transfer services. All ... is now once again fully "DTC Eligible", and ...
(Date:12/17/2014)... LOS ANGELES , Dec. 17, 2014 /PRNewswire/ ... that the US Patent and Trademark Office (USPTO) ... candidate ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting ... glioblastoma. The claims of US Patent No. 8,871,211, ... treating neural cancer by administering a dendritic cell ...
(Date:12/17/2014)... , Dec. 17, 2014 PCCA ... Approved ( http://bit.ly/1382OkS ) program seal for ... community. The program highlights medical practices, materials and ... "autism-community friendly." Children affected by autism ... can be exacerbated by ingredients found in food ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 2Parents Of Children With Autism Spectrum Disorder Have New Options When Administering Medications 3
(Date:12/21/2014)... Serious Buyer, Andrew Hawley from Vintage Rock ... the Doors International Ballroom at the Hilton Hotel in ... only time that Morrison's mother would see her son ... According to Hawley, “This would be the Doors only ... Roller Rink earlier that year and would return to ...
(Date:12/21/2014)... Over the past 39 years, NES Health ... emergency departments across the nation, from quality of medical ... into an innovative suite of tools, systems, and programs ... the patient experience. , NES Health, a leading ... services for hospitals, announced the development and launch of ...
(Date:12/21/2014)... 21, 2014 Theme and ... new intro plugin for Final Cut Pro X entitled ... logos, and more with absolute ease.” Said Christiana Austin, ... the tools needed to easily animate their media inside ... Pro X users to animate pictures, videos, logos, and ...
(Date:12/21/2014)... Vancouver, WA (PRWEB) December 21, 2014 CannabisClassifieds.com ... website redesign. The only one of its kind, the ... to find local marijuana for 14 years running. It ... Angie’s List to make cannabis readily available to the masses. ... way to grasping the golden ring of public approval. ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Concept Plus, LLC. ... engineering firm headquartered in Fairfax, VA., today announced it ... its Fast 50 list, which ranks the fastest growing government ... from 2009 to 2013. , This is the first year ... it ranked # 20 with a 95.92% compound annual growth ...
Breaking Medicine News(10 mins):Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:CannabisClassifieds.com Maintains its “Craigslist for Cannabis” Standing with Website Re-launch 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2
... toxins enter the cells, but before the toxins can kill, ... brain cancer cells are even better than healthy cells at ... cells tend to die before brain cancer cells. Especially in ... the University of Colorado Cancer Center have discovered a way ...
... an HIV-infected partner is the single most important factor influencing ... a multinational study of heterosexual couples in sub-Saharan Africa. The ... calculated the risk of HIV-1 transmission per act of sexual ... about 1 per 900 coital acts. The findings also confirmed ...
... The ideal number of embryos to implant during in-vitro fertilization ... be more than three, according to a new study that ... about 124,000 IVF cycles that resulted in 33,500 live births. ... ages who had two embryos implanted than among those who ...
... News) -- A genetic mutation that causes a rare ... has been identified by scientists. Symptoms of the ... hives (cold urticaria), according to the report published online ... England Journal of Medicine . The U.S. National ...
... News) -- A small study that offers new insight into ... effective treatments for people with drinking problems. Researchers used ... alcohol in the brains of 13 heavy drinkers and a ... In all of the participants, drinking alcohol triggered the ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
Cached Medicine News:Health News:Selectively stopping glutathione sensitizes brain tumors to chemotherapy 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 3Health News:Three Embryos Are Too Many for IVF: Study 2Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Alcohol Targets Brain 'Reward Centers' in Heavy Drinkers 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
This blanket gently surrounds the child with temperature-controlled air. Use one or both of the enclosed clear plastic drapes to keep warmed air near the skin....
The sterile cardiac blanket is utilized during surgical procedures that require access to the upper half of the body. Warms groin area while providing easy access to the area through a perforated ope...
The new Cardiac ThermoWrap provides precise and continuous management of body temperature, thermally protecting your patient in this exceedingly complex environment....
Medicine Products: